AMAnna Marciniak

Anna Marciniak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Marciniak has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Left ventricular assessment with artificial intelligence increases the diagnostic accuracy of stress echocardiography

    by Jamie M O’dRiscoll, William Hawkes, Arian Beqiri, Angela Mumith, Andrew Parker, Ross Upton, Annabelle McCourt, William Woodward, Cameron Dockerill, Nikant Sabharwal, et al.

    To evaluate whether left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS), automatically calculated by artificial intelligence (AI), increases the diagnostic performance of stress echocardiography (SE) for coronary artery disease (CAD) detection. SEs from 512 participants who underwent a clinically indicated SE (with or without contrast) for the evaluation of CAD from seven hospitals in the UK and US were studied. Visual wall motion scoring (WMS) was performed to identify inducible ischaemia. In addition, SE images at rest and stress underwent AI contouring for automated calculation of AI-LVEF and AI-GLS (apical two and four chamber images only) with Ultromics EchoGo Core 1.0. Receiver operator characteristic curves and multivariable risk models were used to assess accuracy for identification of participants subsequently found to have CAD on angiography. Participants with significant CAD were more likely to have abnormal WMS, AI-LVEF, and AI-GLS values at rest and stress (all P < 0.001). The areas under the receiver operating characteristics for WMS index, AI-LVEF, and AI-GLS at peak stress were 0.92, 0.86, and 0.82, respectively, with cut-offs of 1.12, 64%, and −17.2%, respectively. Multivariable analysis demonstrated that addition of peak AI-LVEF or peak AI-GLS to WMS significantly improved model discrimination of CAD [C-statistic (bootstrapping 2.5th, 97.5th percentile)] from 0.78 (0.69–0.87) to 0.83 (0.74–0.91) or 0.84 (0.75–0.92), respectively. AI calculation of LVEF and GLS by contouring of contrast-enhanced and unenhanced SEs at rest and stress is feasible and independently improves the identification of obstructive CAD beyond conventional WMSI.


  • Open Access

    Pulmonary embolism in patients with the Coronavirus Disease 2019

    by Przemysław Kapała, Mattia Versace, Ewelina Tuchendler, Anna Marciniak, Przemysław Guzik

    Coronaviruses are RNA viruses causing infectious diseases. They had been responsible for 15% cases of a common cold before December 2019. With the new strain of coronavirus SARS CoV2 which causes COVID-19 disease, the ongoing pandemic surprised with the severity of symptoms and its course compared to the previously known mild respiratory tract infections. In the end of December 2021, over 274 million people were diagnosed with COVID-19 disease, and the total mortality amounted to nearly 5.4 million deaths in more than 200 countries. One of the potentially fatal complications of COVID-19 is pulmonary embolism (PE). It appears that PE has been associated with several coagulation abnormalities as well as with frequent significantly elevated concentration of D‑dimer's. A higher D‑dimer concentration in blood serum, in turn, has been associated with an increased risk of premature death. Moreover, inflammation, typical in the course of COVID-19, is considered a prothrombotic condition; higher interleukin 6 (Il-6) and C‑reactive protein concentrations have been found in patients with more severe forms of COVID-19. So far, none specific for COVID-19 studies have been available with regard to the diagnosis and treatment of PE. Therefore, the practical approach is based on the experience of other groups of patients. Prevention of thrombotic events seems reasonable, at least in COVID-19 patients with the risk factors of developing venous thromboembolism. Low‑molecular‑weight heparins are most commonly prescribed (e.g. enoxaparin, dalteparin). Following the confirmed definite PE diagnosis, proper anticoagulation or, if necessary, thrombolytic treatment must be introduced.


  • Undiagnosed Chronic Obstructive Pulmonary Disease is Highly Prevalent in Patients Referred for Dobutamine Stress Echocardiography with Shortness of Breath

    by Jamie M. O’dRiscoll, Dimitrios Giannoglou, Ibrahim Bashar, Konstantina Kipourou, Emanuela Alati, Brendan Madden, Anna Marciniak, Rajan Sharma

    Purpose Shortness of breath (SOB) is a common symptom referral for dobutamine stress echocardiography (DSE). Patients with SOB and a normal DSE have worse long-term outcome than the general population. This suggests multiple aetiologies are involved. The purpose of this study was to assess the prevalence and clinical significance of undiagnosed COPD amongst patients referred for a DSE with SOB. Methods We prospectively studied 114 patients referred for DSE with SOB without prior evidence of lung disease (mean age 64.9 ± 18.5 years, 60 male). Respiratory function testing using spirometry was performed on all patients on the day of their DSE. The study end-points were cardiac events and total mortality. Results Respiratory function testing and DSE was performed in all patients and COPD was highly prevalent (n = 93). Multivariate Cox regression analysis was used to estimate the effect of dyspnoea on non-fatal cardiac events (NFCE) and all-cause mortality. Over a mean follow-up of 4.5 ± 2.6 years, the composite end-point of NFCE and all-cause mortality occurred in 62.7% and 16.7% patients, respectively. COPD (HR 1.27; 95% CI 1.17–1.93), previous myocardial infarction (HR 1.84; 95% CI 1.06–3.2), myocardial ischaemia (HR 2.56; 95% CI 1.48–4.43), peak wall motion score index (HR 4.66; 95% CI 2.26–9.6), and mitral E/E’ (HR 1.21; 95% CI 1.1–1.33) were significantly associated with a NFCE. Myocardial ischaemia (HR 4.43; 95% CI 1.24–15.81) was the only independent predictor of all-cause mortality. Conclusion Undiagnosed COPD is highly prevalent and independently associated with worse outcome amongst patients with SOB referred for DSE. Symptom presentation is therefore an important consideration when interpreting DSE results.


  • Open Access

    Cardiovascular imaging in the acute phase of coronavirus disease 2019 (COVID-19)

    by Wioletta Sacharczuk, Rafał Dankowski, Anna Marciniak, Anna Szałek-Goralewska, Andrzej Szyszka

    The coronavirus disease 2019 (COVID-19) has become the most critical healthcare issue worldwide since the pandemic was announced in March 2020. Although respiratory symptoms remain the critical characteristic feature of COVID-19 (with acute respiratory syndrome as the leading cause of mortality), the disease also affects other organs. In fact, the involvement of the cardiovascular system during COVID-19 may include acute coronary symptoms, acute heart failure and myocarditis, arrhythmias, cardiac tamponade, pulmonary embolism, and right ventricular failure due to a high-pressure mechanical ventilation. It is vital to note that all of the abovementioned disorders require specific, pandemic-adapted imaging algorithms. This brief review aims to discuss different cardiac imaging modalities to demonstrate their effectiveness in managing patients in the acute phase of COVID-19.